Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Is VISX [EYE] the Next RMBS? -- Ignore unavailable to you. Want to Upgrade?

To: Thai Chung who wrote (18)	8/2/2000 2:20:51 AM
From: The Prophet	Respond to of 24

Thanks, Thai. Good find. This company is just entering the S-curve. If my guess about future patent litigation pans out, we will begin to see the RMBS/VISX parallels. Prophet

To: Thai Chung who wrote (18)	9/20/2000 1:16:27 AM
From: The Prophet	Read Replies (1) \| Respond to of 24

Looks like the first step towards being Rambusized: September 19, 12:34 pm Eastern Time Press Release Patent Office Issues VISX '388 Patent Following Reexamination SANTA CLARA, Calif.--(BW HealthWire)--Sept. 19, 2000--VISX, INCORPORATED (NYSE Symbol: EYE - news) announced today that the U.S. Patent and Trademark Office has issued a Reexamination Certificate in the reexamination of VISX's U.S. Patent No. 5,108,388, known as the `388 Patent. During the reexamination VISX amended the original five claims of the patent and added 60 new claims that pertain to methods of performing laser vision correction. The patent will expire in 2009. VISX is the worldwide leader in the development of refractive laser technology. VISX systems are commercially available in the United States and markets worldwide. Contact: VISX Lola Wood, 877/463-6847 ir@visx.com visx.com